Travere Therapeutics, Inc. (TVTX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Travere Therapeutics, Inc.
Address
3611 Valley Centre Drive
San Diego, CA 92130
United States of America (the)
Phone
888 969 7879
Website
Sector
Healthcare
Industry
Biotechnology
Employees
497
First IPO Date
November 08, 2012
Key Executives
| Name | Title | Pay | Year Born |
| Eric Dube | President, Chief Executive Officer & Director | 1.83M | 1973 |
| Elizabeth E. Reed | Chief Legal Officer, General Counsel & Secretary | 713,634 | 1971 |
| Christopher Cline | Chief Financial Officer | 929,557 | 1985 |
| William E. Rote | Chief Research Officer | 935,108 | 1963 |
| Peter Heerma | Chief Commercial Officer | 940,394 | 1971 |
| Jula Inrig | Executive VP, Head of Research & Development and Chief Medical Officer | 1.01M | 1975 |
| Sandra Calvin | SVP & Chief Accounting Officer | 0 | 1966 |
| Casey Logan | Chief Business Officer | 0 | N/A |
| Angela Giannantonio | Chief People Officer | 0 | N/A |
| Nivi Nehra | Vice President of Corporate Communications & Investor Relations | 0 | N/A |
Description
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
